NDAORALTABLETPriority Review
Approved
Jul 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
9
Mechanism of Action
Angiotensin 2 Receptor Antagonists
Pharmacologic Class:
Angiotensin 2 Receptor Blocker
Indications (6)
Clinical Trials (5)
Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure)
Started Dec 2024
33 enrolled
Pediatric Chronic Heart Failure
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Started Sep 2023
1,125 enrolled
Hypertension
Real World, Pharmacy-assessed Adherence to New Onset Entresto® (Sacubitril/Valsartan) in Patients With Chronic Heart Failure
Started May 2023
0Heart Failure
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
Started Jan 2023
1,405 enrolled
Essential Hypertension
Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.
Started Mar 2022
251,831 enrolled
Chronic Heart Failure
Loss of Exclusivity
LOE Date
May 9, 2036
123 months away
Patent Expiry
May 9, 2036
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 9388134 | Nov 8, 2026 | U-1723 | |
| 9388134*PED | May 8, 2027 | — | |
| 8877938 | May 27, 2027 | SubstanceProduct | — |
| 8877938*PED | Nov 27, 2027 | — | |
| 9937143 | Aug 22, 2033 | U-3084 |